智通财经APP获悉，基石药业-B(02616)午前涨超8%，近两周交易日累计涨近60%。截至发稿，涨2.95%，报34.85港元，成交额1.26亿港元。
消息面上，基石药业-B发布公告，舒格利单抗(择捷美®)GEMSTONE-303研究结果在国际顶级医学期刊《美国医学会杂志》(JAMA)主刊正式发表。据介绍，GEMSTONE-303是一项随机、双盲、安慰剂对照的III期注册性临床试验，旨在评估舒格利单抗联合CAPOX化疗方案(奥沙利铂+卡培他滨)对比安慰剂联合CAPOX化疗方案，作为一线治疗无法手术切除的PD-L1CPS≥5的局部晚期或转移性胃或胃食管结合部(G/GEJ)腺癌的疗效和安全性。该研究的协同主要终点为OS和研究者评估的PFS，次要研究终点包括盲态独立中心审阅委员会(BICR)评估的PFS、客观缓解率(ORR)及缓解持续时间(DoR)。
基石药业首席执行官、研发总裁及执行董事杨建新博士表示：“很荣幸舒格利单抗GEMSTONE-303研究数据能发表于国际顶级期刊JAMA，该研究是舒格利单抗联合化疗成为PD-L1CPS≥5胃/胃食管结合部(G/GEJ)腺癌患者一线标准疗法的重要基础。截至目前，舒格利单抗已在中国获批5项适应症。与此同时，我们也已拓展舒格利单抗在海外的注册上市，并针对其商业化在多个国际市场达成合作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.